MARKET INSIGHTS

Global (S)-1-(3-Methoxyphenyl) ethylamine (CAS 82796-69-8) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(S)-1-(3-Methoxyphenyl) ethylamine is a chiral amine compound characterized by its high enantiomeric purity and a methoxy substituent at the meta position of the phenyl ring. It serves as a critical chiral building block and resolving agent in asymmetric synthesis, widely employed in the production of pharmaceuticals, agrochemicals, and specialty fine chemicals. Its well‑defined stereochemistry makes it particularly valuable in the synthesis of enantiomerically pure active pharmaceutical ingredients (APIs).

The market is steadily expanding, driven by growing demand for chiral intermediates in pharmaceutical manufacturing and the increasing emphasis on enantioselective synthesis across the life sciences sector. Furthermore, advancements in asymmetric catalysis and continuous process chemistry are broadening its applicability. Key suppliers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and several specialized fine chemical manufacturers across China, Europe, and North America.

(S)-1-(3-Methoxyphenyl) ethylamine (CAS 82796-69-8) Market – View in Detailed Research Report

Top 10 Companies in the Market

1. TCI Chemicals (Japan)

Headquarters: Tokyo, Japan
Key Offering: Pharmaceutical‑grade chiral amines, custom synthesis services

TCI’s long‑standing expertise in enantioselective chemistry, coupled with a GMP‑compliant production line, positions it as a trusted partner for drug developers seeking high‑purity intermediates. The company routinely delivers ≥99% ee products to global CROs and CDMOs, supporting complex API routes.

• Advanced asymmetric hydrogenation platform
• Rapid scale‑up capability for pilot to commercial volumes
• Dedicated technical support for reaction optimisation

2. Sigma‑Aldrich (Merck KGaA) – MilliporeSigma (USA)

Headquarters: Rahway, New Jersey, USA
Key Offering: Broad catalogue of chiral building blocks, high‑purity reagents

As a global supplier, MilliporeSigma offers a wide range of chiral amines with rigorous quality controls, enabling pharmaceutical chemists to streamline early‑stage synthesis and reduce development timelines.

• Extensive library of enantiomerically pure intermediates
• Integrated analytical services for ee verification
• Flexible packaging for laboratory to pilot scale

3. Tokyo Chemical Industry Co., Ltd. (Japan)

Headquarters: Tokyo, Japan
Key Offering: Custom resolution services, scalable chiral synthesis

TCI’s focus on enzymatic resolution and chiral acid‑based methods delivers cost‑effective, high‑yield solutions for both research and commercial clients.

• High‑throughput resolution platform
• On‑demand synthesis for niche intermediates
• Strong collaboration with academic research groups

4. Enamine Ltd. (Ukraine)

Headquarters: Kyiv, Ukraine
Key Offering: Custom synthesis, library development, and rapid delivery

Enamine’s agile manufacturing model supports bespoke projects, making it an attractive partner for early‑stage drug discovery teams that require quick access to chiral reagents.

• Rapid turnaround for custom orders
• Comprehensive stereochemical analysis
• Support for medicinal chemistry optimisation

5. PharmaBlock Sciences (China)

Headquarters: Shenzhen, China
Key Offering: Scalable asymmetric reduction, cost‑efficient production

PharmaBlock’s investment in catalytic technologies enables large‑scale production of chiral amines at competitive pricing, appealing to generic drug manufacturers.

• High‑yield catalytic processes
• Optimised supply chain for raw materials
• Dedicated R&D for new chiral platforms

6. Hairui Industries Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Enzymatic resolution, custom synthesis

Hairui’s focus on green chemistry and enzymatic methods aligns with the growing demand for sustainable production routes.

• Eco‑friendly synthesis processes
• Flexible scale‑up from lab to pilot
• Collaborations with CROs on early‑stage projects

7. Capot Chemical Co., Ltd. (China)

Headquarters: Guangzhou, China
Key Offering: Chiral ligand development, specialty fine chemicals

Capot’s expertise in chiral ligand synthesis supports advanced catalytic applications, extending the use of (S)-1-(3-Methoxyphenyl) ethylamine beyond API synthesis.

• High‑purity ligand production
• Support for asymmetric catalysis research
• Strong analytical capabilities

8. Asymchem Laboratories (China)

Headquarters: Wuhan, China
Key Offering: Tailored chiral synthesis, small‑batch production

Asymchem’s flexible production model allows rapid iteration of chiral routes, which is valuable for exploratory medicinal chemistry programs.

• Rapid method development
• Small‑batch, high‑purity outputs
• Collaboration with academic partners

9. Biosynth (Switzerland)

Headquarters: Zurich, Switzerland
Key Offering: Custom synthesis, analytical services

Biosynth’s precision manufacturing and rigorous quality controls make it a preferred supplier for European pharmaceutical firms.

• High‑precision synthesis
• Comprehensive quality documentation
• Dedicated support for regulatory submissions

10. MilliporeSigma (USA)

Headquarters: Burlington, Massachusetts, USA
Key Offering: High‑purity chiral reagents, research support

MilliporeSigma’s extensive distribution network and robust R&D resources enable rapid access to chiral intermediates across North America.

• Broad product portfolio
• Integrated analytical support
• Fast logistics for laboratory and pilot scale

Download FREE Sample Report

Get Full Report

Market Outlook

The trajectory of the (S)-1-(3-Methoxyphenyl) ethylamine market reflects a sustained demand for high‑purity chiral intermediates. Pharmaceutical companies are increasingly incorporating stereochemically defined building blocks early in the development pipeline, which drives procurement of enantiomerically pure reagents. The continued evolution of asymmetric catalysis and process intensification technologies will further lower production costs and improve scalability, encouraging broader adoption across both established and emerging markets.

Emerging Trends

• Integration of continuous flow processes for chiral synthesis, reducing batch variability and enhancing throughput.
• Expansion of chiral amine applications into agrochemical development, where stereochemistry can influence efficacy and environmental profile.
• Growth of green chemistry initiatives, promoting enzymatic and biocatalytic routes that minimise hazardous reagents.
• Increasing reliance on contract development and manufacturing organizations (CDMOs) for early‑stage synthesis, creating a demand for flexible, high‑purity intermediates.